Protagenic Therapeutics, Inc. (PTIX)
| Previous Close | 1.4500 |
| Open | 1.4500 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 1.3200 - 1.4800 |
| 52 Week Range | 0.6800 - 2.3200 |
| Volume | |
| Avg. Volume | 11,819 |
| Market Cap | 6.143M |
| Beta (5Y Monthly) | 0.38 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.1500 |
| Earnings Date | May 15, 2024 - May 19, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
ACCESSWIREProtagenic Therapeutics’ Innovative Peptide PT00114 to be Highlighted at Boston Summit
Chief Operating Officer to Present Key Advances at Peptide Therapeutics Summit NEW YORK, NY / ACCESSWIRE / April 17, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a pioneer in biopharmaceutical research, announced today that Dr. Andrew Slee, ...
- ACCESSWIRE
Protagenic Therapeutics Reports Fourth Quarter and Full Year 2023 Results
Transitioned from Pre-Clinical to Clinical Stage company in FY 2023 Phase 1/2a trial, designed to assess both healthy volunteers and patients diagnosed with Treatment-Resistant Depression, PTSD or Generalized Anxiety Disorder, progressing through ...
- ACCESSWIRE
Protagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric Disorders
Next clinical progress update expected in April 2024 NEW YORK, NY / ACCESSWIRE / March 27, 2024 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a leader in biopharmaceutical innovation, advances its mission to develop cutting-edge treatments for stress-related ...
